Yamaguchi K
Growth Factor Division, National Cancer Center Research Institute, Tokyo, Japan.
Gan To Kagaku Ryoho. 1991 Mar;18(3):343-9.
Hypercalcemia is the most frequent paraneoplastic syndrome observed in cancer patients. This morbidity can be divided into two categories: one is hypercalcemia induced by severe bone metastases; the other the elaboration of hypercalcemic factors by solid tumors, termed humoral hypercalcemia of malignancy (HHM). With regard to humoral factors responsible for HHM, a protein with parathyroid hormone (PTH)-like activity, designated PTH-related protein (PTHrP), was isolated from a cancer cell line established from a hypercalcemic patient's lung cancer tissue, and the structure of PTHrP mRNA was identified. Since the biological activity of PTHrP explained most of the clinical and laboratory findings of HHM patients and recent clinical studies indicated the very close relationship between the development of HHM and the production of PTHrP by tumor, PTHrP is now regarded to be the primary candidate for the actual factor responsible for HHM.
高钙血症是癌症患者中最常见的副肿瘤综合征。这种病症可分为两类:一类是由严重骨转移引起的高钙血症;另一类是实体瘤产生高钙血症因子,称为恶性肿瘤体液性高钙血症(HHM)。关于导致HHM的体液因子,从一名高钙血症患者肺癌组织建立的癌细胞系中分离出一种具有甲状旁腺激素(PTH)样活性的蛋白质,称为甲状旁腺激素相关蛋白(PTHrP),并确定了PTHrP mRNA的结构。由于PTHrP的生物学活性解释了HHM患者的大多数临床和实验室检查结果,且近期临床研究表明HHM的发生与肿瘤产生PTHrP之间存在密切关系,因此PTHrP现在被认为是导致HHM的实际因子的主要候选者。